Zai Lab Acquires China Rights to Novel Autoimmune Drug in $175 Million Deal
January 07, 2021 at 07:05 AM EST
Shanghai 's Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up to $175 million in upfront and near-term payments. argenex's efgartigimod is close to US approval for use in patients with generalized myasthenia gravis. Efgartigimod is an investigational antibody fragment that binds to the neonatal Fc receptor (FcRn) to reduce disease-causing immunoglobulin G antibodies. argenx is a Dutch company that has offices in Belgium , the US and Japan . More details.... Stock Symbols: (NSDQ: ZLAB; HK: 9688) (Euronext & NSDQ: ARGX) Share this with colleagues: // //
